Crush Your Workout Goals Using Only Group Fitness Classes By Following This Plan
More and more guys are embracing group fitness. Why? Because group classes deliver science-backed muscle-building and cardio-enhancing tactics. Not sure how to get the most out of the new group fitness scene? We've got everything you need right here.
THERE'S NEVER BEEN a better time to jump into the group fitness scene then now. And contrary to what your average big box gym trainer may tell you, if you build your group fitness training schedule out right, you can easily get into crazy-good shape doing only group classes. The trick: You have to have a plan. And no, that plan shouldn't involve four straight days of spin (or yoga... or any one group class, really!). One of the biggest traps you want o avoid when building a group schedule with a focused training goal is this: Repeating a single cardio-style class over and over. If you do that, you'll miss out on other key fitness traits that you'll want to train to stay healthy in the long term (think: strength and mobility). The flipside? Don't be a serial class-hopper. If your schedule has too much variety, you'll never go to group class consistently enough to truly understand the exercises and techniques that the class is trying to teach you.
So before you start bouncing from Rumble to CrossFit to the zen-est yoga class you can find, build out a smart, long-term plan that takes your own personal fitness goals into account. Your first step in that journey: Deciding what you want out of the gym. So take a few minutes to ponder that. Do you want to build muscle? Prep for a 5k? Lose a little weight?
After you've uncovered your fitness goal, build a schedule that leverages the best of what your group fitness scene has to offer. And no, this may not be as hard or expensive as it seems (especially if you're in a city!), because companies like ClassPass are built to help you gain entry to multiple group studios with just a single membership. Just make sure you read the description of every class you book so you understand exactly how it can help you reach your goals. (Most studios run different kinds of classes throughout the day/week, some focusing on strength, others focusing on cardio, and others serving hybrid goals. So no, not all F45 classes will truly build strength.)
And yes, we know all of this can seem overwhelming. That's why we built this five-day group fitness roadmap, which guides you through the perfect class structure to help you reach your fitness goals.
Your Goal: Build Muscle
We know what you might be thinking: there's no way I'm building muscle with a bunch of medium-weight dumbbells in a group class. Except it is possible, if you prioritize tried-and-true strength training fundamentals. And you'll need to train hard. At least once in every group workout with weights, aim to move weights heavy enough that, in the final five seconds of an interval, you have a little doubt whether you can complete the set.
Why? Because progressive overload is the key to muscle-building. You can't just hold onto the same dumbbells you've been grabbing since day one and expect to see bigger biceps (trust us. We've tried). Not sure how or when to go heavier on an exercise? If you feel good after one set of a move, call the trainer over during the rest period, and ask them to watch your next round and evaluate whether you should grab bigger bells.
If muscle-building is indeed your goal, keep that as the central focus in your group routine. Aim to choose THREE strength-style workouts a week (but don't do more than this, since group strength workouts often focus on total-body strength, and you don't want to pile drive your entire body too often). Augment that with ONE cardio workout a week (remember that better cardio capacity will stealthily help your strength work, giving you the endurance to pile up more reps). To keep your mind fresh (and aid in recovery), add in ONE mobility-style or recovery-focused workout a week.
Your Goal: Improve Cardio
Let's face it: lonely post-lift treadmill sessions get boring AF. Group fitness was built for cardio—pumping music, peer pressure to go harder, high energy. And, you don't need to suffer through relentless burpees to get it in. There's a cardio class now for everyone. Pro-tip, though: Don't completely neglect strength training. If you build muscle smartly, it can boost your ability to dominate cardio classes, letting you generate extra force with every single stride on the treadmill or pull of the rower.
Create a healthy balance of cardio and strength with your workout plan. Aim for TWO cardio-based workouts, and pick ones that feel best on your body; if a high impact treadmill class isn't for your knees, swap out for a cycle or rowing based class. Then build in a little strength work: Including TWO strength-based workouts will keep your muscles primed for everyday movement, prevent injury, and improve your speed and endurance, too (underrated contributors to better cardio workouts, by the way!). Of course, you'll also need to allow time for your body to recoup, so opt for ONE mobility-style or recovery-based class.
Your Goal: Lose Weight
Weight loss is complicated. At its most basic, it's about calories in versus calories out. Burn more calories than you intake, and your body will use excess fat for fuel. Theoretically, it sounds like the workout that burns the most calories is the most optimal for weight loss, right?
Not quite. Of course, you want to ensure you get a healthy mix of strength training and cardio, to build functional strength and promote heart health. But, ultimately the workout routine that will burn the most calories will be the one you come back to, day in and day out. So, play around with your routine—so play around with your routine, but gradually work to settle into (and then stick with) a handful of classes that you like. This will enable you to gradually progress and improve in each class, and over time, that progression will become part of the fun (and keep you coming back for more!).
Above all, you want your workout routine to be fun and full of variety and also to let you experience new things. Sure, you'll still need to eat your vegetables (factor in ONE to TWO strength-based workouts per week, and ONE cardio-based workout per week)—but you want to prioritize enjoyment above all. Opt for ONE wildcard choice per week, partly so you can play around and have fun, but also because often, new tasks burn more calories—simply because our body's are inefficient at new tasks. And yes, this schedule can take a toll on your body. So make sure to pepper in ONE mobility or recovery-based class to keep you feeling spry.
The ClassPass Sweat Sessions We Love Most
ONCE YOU'VE CHOSEN a fitness goal and mapped out the class types you'll need to take, you'll be ready to head to ClassPass and pick your sessions. Use this list of our favorite ClassPass classes (sorted by strength, cardio, and recovery!) as a starting point for you to build your early list.
Strength-Based Classes We Love
Elements of a good strength class: a good trainer to provide accurate movement demos, a training program that prioritizes heavy compound lifts and accessory movements, and a timeline that allows you to challenge yourself with proper work and rest periods. Here are a few of our favorites.
MADabolic's Durability class puts your strength and stamina to the test. Their program follows a strict 12-week cycle where members will build, peak, and deload muscle-building compound movements to truly strength train like the athletes.
Get an all-in-one option with F45 Training. Their weekly schedule runs 3 strength days, 2 conditioning days, and two hybrid days a week.
If you're opting for group fitness to find a community, Burn Bootcamp is your place. Build muscle and strength through classic compound movements like squats, lunges, deadlifts, pushups, and rows—all with the encouragement of your classmates.
Thought OTF was all about cardio? Think again. Their Strength50 class is 50 minutes of floor work that incorporates dumbbells, ab wheels, TRX straps, and more to get you a great full body workout.
Okay, you might not see a ton of your buddies in a barre class, but it's worth giving it a shot. Why? Slow movements and pulsing will put your muscles to the test in this barre-inspired class that promotes joint stability, balance, and muscular endurance—three things that will benefit your bigger lifts, and athletic ability on the field or the court.
Cardio-Based Classes We Love
Group fitness was bred for cardio. These high energy classes will get your heart pumping and sweat flowing, with the help of smart trainers and welcoming community.
Don't think cardio equates to treadmill. Rowing provides a full body workout that will get your heart pumping, and improve lower body and back strength—and RowHouse is centered on it.
Behind us are the days of confusing cycle classes with hard-to-match paces and constant up-down. Cyclebar provides great no-frills cycling, accompanied with data points that tells you exactly how you did compared to everyone else—perfect if you have a competitive side.
OrangeTheory started a group fitness revolution when they opened their first location in 2010. Now, with over 1,500 studios worldwide, they've mastered their craft—especially when it comes to cardio. All their classes (with the exception of the Strength50 we mentioned earlier) will challenge your stamina with a mix of treadmill, rower, and fitness exercises.
Floyd Mayweather Jr. won't be your IRL trainer here, but he did design this workout program. You'll learn everything you need to know to nail your first knockout in their Boxing Fundamentals class, and get a great cardio and power workout while you're at it.
Mobility/Recovery Classes We Love
It's easy to neglect your mobility. When you don't have time, the first thing you're going to skip is your 20-minute stretch cooldown. Keep it on your schedule by scheduling a class that you have to show up to.
We don't need to lecture you on yoga's benefits to the body (and mind). It's a perfect addition to your recovery day to promote mobility and stability. Even if you're not very flexible, Corepower has a 'reformative stretch' class to get your joints moving.
You've seen the viral videos of Glenn Powell, LeBron James, and even Kansas City Chief's players doing pilates—it might be time you hop into the trend too. Club Pilates has beginner-friendly classes that will challenge your mobility and strength all in one.
Okay, okay—this isn't technically a class, but a StretchLab session does pair you with a trained practitioner who is there to work through all your stiff muscles and joints through assisted stretching.
You Might Also Like
The Best Hair Growth Shampoos for Men to Buy Now
25 Vegetables That Are Surprising Sources of Protein

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
IMV Releases 2025 Ultrasound Market Outlook Report to Support Strategic Planning Across Hospital Imaging Departments
ARLINGTON, Va., July 31, 2025 /PRNewswire/ -- IMV, a Science and Medicine Group company, a leading provider of market intelligence for the medical imaging industry, has published the 2025 Ultrasound Market Outlook Report, providing decision-makers with in-depth insights into the evolving ultrasound landscape across U.S. hospitals, including a comprehensive analysis of all care areas and equipment factors. Now in its latest edition, the report is based on survey responses from 300 U.S hospitals and projects findings to over 4,900 hospitals using ultrasound equipment. Designed for OEMs, hospital administrators, and imaging department leaders, it supports strategic planning across product development, capital investment, marketing, and clinical operations. It offers a holistic view of ultrasound imaging across general radiology, cardiology, OB/Gyn, and other clinical areas, while delivering actionable intelligence on exam volume trends, installed base composition, purchasing behavior, and site operations. What the 2025 Ultrasound Market Outlook Report Delivers: Segmentation of ultrasound patient exam volumes by care area and equipment type, with trends from 2019 to 2024 and projections into 2025. In-depth analysis of installed base mix and equipment adoption, including handheld, laptop/tablet, and cart-based systems. Insights into capital budgets and purchase plans through 2027, including OEM brand loyalty and top decision-making factors. Operational benchmarks, including average FTE staffing, sonographer productivity, and department structure across hospital sizes. Department-level trends in ultrasound innovation, including image-guided procedures, AI adoption, and non-traditional clinical uses. "This report provides a comprehensive overview of the evolving use of ultrasound in diagnostic imaging," said Davin Korstjens, Director of Market Intelligence at Science and Medicine Group. "With updated insights across a range of market dimensions, this report is an essential resource for both OEMs to stay in tune with the market for ultrasound equipment and for providers to understand how their facility is performing compared to their peers." Key Enhancements in the 2025 Edition: Expanded analysis across all ultrasound form factors, including deeper insights into handheld, laptop/tablet, and cart-based systems. Updated trend coverage focused on image guidance, artificial intelligence, handheld system satisfaction, and new procedural applications. Refreshed Executive Summary and redesigned format, with 159 pages and over 125 visual exhibits in a PowerPoint presentation to support strategic decision-making. Report Resources: Access or Purchase Now: 2025 Ultrasound Market Outlook Download A Free Report Sample View the Full Table of Contents (TOC) For more information, visit About IMV IMV Medical Information Division, established in 1977, is a trusted marketing research and consulting firm that specializes in the dynamic fields of diagnostic imaging and clinical diagnostics. Our commitment to in-depth market analysis and comprehensive research services empowers clients to excel in strategic planning, enhance customer satisfaction, drive product development, and launch successful sales initiatives. All of IMV's reports and data solutions are based on primary research by diagnostic imaging experts. As a reliable provider of market intelligence, IMV gives you the comprehensive information you need to stay two steps ahead and make decisions with confidence! For media inquiries, please contact: Media ContactIMV Marketing(703) View original content to download multimedia: SOURCE IMV Medical Information Division
Yahoo
6 minutes ago
- Yahoo
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private placement and an additional $20 million in a secured subordinated promissory note convertible to prepaid revenue share • Medtronic and Orchestra BioMed expand strategic collaboration to provide pathway for development of AVIM therapy-enabled leadless pacemakers NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, 'Orchestra BioMed' or the 'Company'), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the Company has secured $70 million in new capital from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND, 'Ligand') and Medtronic, plc. (NYSE: MDT, 'Medtronic') to advance its late-stage partnered cardiology programs. Simultaneously, Orchestra BioMed and Medtronic, which have an existing strategic collaboration for atrioventricular interval modulation ('AVIM') therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients, have amended their agreement to include the potential future development of AVIM therapy-enabled leadless pacemakers. Unlike traditional pacemakers that are placed in a patient's chest with leads (or wires) running to the heart, minimally-invasive Medtronic Micra™ leadless pacemakers are implanted directly into the heart, reducing potential sources of complications. Ligand $40 million Investment Todd Davis, Chief Executive Officer of Ligand commented: 'We are pleased to partner with Medtronic and Orchestra BioMed in this important endeavor. This investment expands our pipeline of development-stage products and demonstrates our confidence in Orchestra BioMed's scientific advancements, as well as the strong capabilities of its partner, Medtronic. We are proud to support Orchestra BioMed as they develop novel high-impact, device-based therapies such as AVIM therapy and Virtue SAB targeting high-risk patient populations with hypertension and arterial disease, two of the most significant global health challenges.' David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed stated, 'Ligand has been one of the inspirations for our partnership-driven approach to creating long-term, capital-efficient value through royalty-based collaborations. We are thrilled to welcome them as a strategic capital partner. Ligand's decision to invest in our partnered programs and our team reflects our shared conviction in the transformative potential of both AVIM therapy and Virtue SAB – our late-stage flagship technologies aimed to address important unmet medical needs in large, established global markets. This transaction provides foundational financial support to enable our potential achievement of key value creating milestones for both of our high-impact clinical programs.' Under the terms of the agreement, Ligand will pay $20 million to Orchestra BioMed at closing with an additional $15 million to be funded, subject to certain conditions precedent, at the nine-month anniversary of the transaction closing date. Ligand has also agreed to invest an additional $5 million to purchase shares of the Company's common stock in an equity private placement at the public offering price per share in Orchestra BioMed's next public offering of its equity securities. In exchange, Ligand will receive a low double-digit royalty on the first $100 million in commercial revenues from Orchestra's AVIM therapy and Virtue SAB programs in all indications. Ligand will also earn a mid-single-digit royalty on annual revenues exceeding $100 million in commercial revenues from AVIM therapy in the uncontrolled hypertension and increased cardiovascular risk indication and Virtue SAB in coronary artery disease indications. Medtronic $30 million Additional Investment & Future Leadless AVIM Therapy Device Development Robert C. Kowal, M.D., Ph.D., Vice President and General Manager of Cardiac Pacing Therapies within the Medtronic Cardiac Rhythm Management operating unit, commented: 'Our expanded investment in Orchestra BioMed reflects confidence in their clinical progress. Broadening our collaboration to include integrating AVIM therapy into future leadless pacing technology reaffirms our commitment to transform care for patients who need pacing therapy and have uncontrolled hypertension.' Mr. Hochman added, 'Medtronic continues to be an outstanding partner for the AVIM therapy program. We believe their $30 million additional commitment to Orchestra BioMed reflects their belief in the clinical and commercial potential for this therapy to benefit patients with uncontrolled hypertension and increased cardiovascular risk in the pacemaker population. Expanding our existing collaboration to provide for potential future integration of AVIM therapy into a leadless pacemaker system deepens our strategic alignment and creates a potential pathway for patients to benefit from both AVIM therapy and cutting-edge leadless pacing technology, simultaneously.' Subject to the terms of the agreement, Medtronic's $30 million additional investment commitment to Orchestra BioMed includes a $10 million agreement to purchase shares of the Company's common stock in a private placement at the public offering price in the Company's next public offering of its equity securities. Medtronic also made a $20 million commitment to purchase a five-year term secured subordinated promissory note, to be funded in nine months which automatically converts to a prepaid revenue share upon U.S. Food and Drug Administration ('FDA') approval of AVIM therapy. The prepaid revenue share will be credited back to Medtronic at a low double-digit percentage of actual AVIM therapy revenue share paid to Orchestra BioMed, up to $40 million in cumulative revenue share. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Ligand's business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Ligand's business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate revenue. Ligand operates two infrastructure-light royalty generating technology IP platform technologies. Ligand's Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand's NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. Ligand uses its investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. About Orchestra BioMed Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is AVIM therapy for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing Virtue SAB for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. The Company has received four Breakthrough Device Designations from the FDA across these two core programs, reflecting the significant potential of its technologies to address high unmet needs in cardiovascular care. For further information about Orchestra BioMed, please visit and follow us on LinkedIn. References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About AVIM Therapy AVIM therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal study will further evaluate the safety and efficacy of AVIM therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM therapy has been granted Breakthrough Device Designation by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk. About Virtue SABVirtue SAB is designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™ through a non-coated microporous AngioInfusion™ Balloon that protects the drug in transit to consistently deliver a large liquid dose overcoming certain limitations of drug-coated balloons. SirolimusEFR delivered by Virtue SAB has been shown in published preclinical series involving hundreds of arterial deliveries to achieve sustained tissue levels well above the known required therapeutic tissue concentration for inhibiting restenosis (1 ng/mg tissue) for the entire critical healing period of approximately 30 days. Virtue SAB demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multi-center prospective, independent core lab-adjudicated clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for specific indications relating to coronary ISR, coronary small vessel disease and peripheral artery disease below-the-knee. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, implementation and design of the Company's planned and ongoing pivotal trials, realizing the clinical and commercial value of the Company's product candidates, the potential safety and efficacy of the Company's product candidates, the ability of the Company's partnerships to accelerate clinical development, and the Company's ability to satisfy funding and closing conditions of the transactions described in this press release. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company's commercial product candidates and ongoing regulation of the Company's product candidates, if approved; the timing of, and the Company's ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading 'Item 1A. Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025 and the risk factor discussed under the heading 'Item 1A. Risk Factors' in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which was filed with the SEC on May 12, 2025. The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law. Contacts For Orchestra BioMed:Investors:Silas NewcombSnewcomb@ Media: Kelsey Kirk-EllisKkirkellis@ For Ligand:Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072
Yahoo
6 minutes ago
- Yahoo
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full maternal UBE3A gene deletion. 'The accelerated enrollment of the Phase 3 Aspire study underscores the urgent need and strong desire for an effective treatment for these patients. Support from the Angelman syndrome community was critical to the achievement of this important milestone for GTX-102 with completion of enrollment in seven months. We are grateful to the study site teams, investigators, and families for their dedication and support,' said Eric Crombez, M.D., chief medical officer at Ultragenyx. 'The continued developmental gains observed in the Phase 1/2 study provide a strong foundation as we advance this program with the potential to address the underlying genetic cause of this disease and enhance the quality of life for children living with Angelman syndrome.' Jean-Baptiste Le Pichon, MD, PhD, FAAP, Interim Division Director, Neurology; Madison Lauren Sargent Endowed Professorship in Neurology/Angelman Syndrome, Children's Mercy and an investigator on the Aspire study, added: 'Today there are thousands of children and adults in the U.S. living with Angelman syndrome, with no cure or hope. To have a treatment in development with the potential to correct the underlying genetic error that forms the basis of Angelman syndrome, restore protein function, and recover function for patients is extremely meaningful. Completing enrollment of this study is a major milestone, and I eagerly look forward to additional data that builds on the promising preliminary results from the previous Phase 1/2 study.' Enrollment in the global Phase 3 Aspire study (NCT06617429) began in December 2024. Participants are randomized 1:1 to receive GTX-102 by intrathecal injection via lumbar puncture or to the sham comparator group for a period of 48 weeks. Participants in the active treatment group will receive three monthly 8 mg loading doses of GTX-102, followed by dosing in a maintenance period that will increase to a maximum dose of 14 mg of GTX-102 quarterly. Participants in the sham comparator group will be eligible to cross over onto treatment after completing their Week 48 assessments. The primary endpoint will be improvement in cognition assessed by Bayley-4 cognitive raw score, and the key secondary endpoint (with a 10% allocation of alpha) will be the Multi-domain Responder Index (MDRI) across the five domains of cognition, receptive communication, behavior, gross motor function, and sleep. Study completion is expected in the second half of 2026 and Ultragenyx plans to move with urgency to provide topline data and progress to regulatory submission. About GTX-102 (apazunersen)GTX-102 (apazunersen) is an investigational antisense oligonucleotide (ASO) therapy delivered via intrathecal administration and designed to target and inhibit expression of the UBE3A-AS to prevent silencing of the paternally inherited allele of the UBE3A gene and reactivate expression of the deficient protein. GTX-102 has been granted Breakthrough Therapy Designation, Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA and Orphan Designation and PRIME designation from the EMA. About Angelman SyndromeAngelman syndrome is a rare, neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. The maternal-specific inheritance pattern of Angelman syndrome is due to genomic imprinting of UBE3A in neurons of the central nervous system (CNS), a naturally occurring phenomenon in which the maternal UBE3A allele is expressed and the paternal UBE3A is not. Silencing of the paternal UBE3A allele is regulated by the UBE3A-AS, the intended target of GTX-102. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. This condition is generally not inherited but instead occurs spontaneously. It is estimated to affect approximately 60,000 people in commercially accessible geographies. Angelman syndrome is a lifelong neurodevelopmental disorder that causes cognitive impairment, motor impairment, balance issues and debilitating seizures. Some individuals with Angelman syndrome are unable to walk and most do not speak. Anxiety and disturbed sleep can be serious challenges in individuals with Angelman syndrome. Although individuals with Angelman syndrome have a normal lifespan, they require continuous care and are unable to live independently. Angelman syndrome is not a degenerative disorder, but the loss of the UBE3A protein expression in neurons results in abnormal communications between neurons. Angelman syndrome is often misdiagnosed as autism or cerebral palsy. There are no currently approved therapies for Angelman syndrome; however, several symptoms of this disorder can be reversed in adult animal models of Angelman syndrome, suggesting that improvement of symptoms can potentially be achieved at any age. About UltragenyxUltragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Forward-Looking Statements and Use of Digital MediaExcept for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx's expectations and projections regarding its future operating results and financial performance, business plans and objectives for GTX-102, expectations regarding the tolerability and safety of GTX-102, anticipated timing of data from ongoing GTX-102 studies, anticipated timing for initiation and completion of GTX-102 studies, and future clinical and regulatory developments for GTX-102 are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals, the ability of the company to successfully develop GTX-102, the company's ability to achieve its projected development goals in its expected timeframes, the risk that results from earlier studies may not be predictive of future study results, risks related to adverse side effects, risks related to reliance on third party partners to conduct certain activities on the company's behalf, smaller than anticipated market opportunities for the company's products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the company's future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx's products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, and its subsequent periodic reports filed with the SEC. In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx's Investor Relations website ( and LinkedIn website ( Ultragenyx Contacts InvestorsJoshua Higair@ MediaJess Rowlands media@